Medicenna Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch MDNAF and buy or sell other stocks, ETFs, and their options commission-free!About MDNAF
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers.
CEOFahar Merchant
CEOFahar Merchant
Employees18
Employees18
HeadquartersToronto, Ontario
HeadquartersToronto, Ontario
Founded2015
Founded2015
Employees18
Employees18
MDNAF Key Statistics
Market cap77.63M
Market cap77.63M
Price-Earnings ratio-9.13
Price-Earnings ratio-9.13
Dividend yield—
Dividend yield—
Average volume112.41K
Average volume112.41K
High today$1.15
High today$1.15
Low today$1.09
Low today$1.09
Open price$1.14
Open price$1.14
Volume49.52K
Volume49.52K
52 Week high$1.46
52 Week high$1.46
52 Week low$0.5732
52 Week low$0.5732
Stock Snapshot
With a market cap of 77.63M, Medicenna Therapeutics(MDNAF) trades at $1.12. The stock has a price-to-earnings ratio of -9.13.
As of 2025-12-06, Medicenna Therapeutics(MDNAF) stock has fluctuated between $1.09 and $1.15. The current price stands at $1.12, placing the stock +2.8% above today's low and -2.6% off the high.
Medicenna Therapeutics(MDNAF) shares are trading with a volume of 49.52K, against a daily average of 112.41K.
During the past year, Medicenna Therapeutics(MDNAF) stock moved between $0.57 at its lowest and $1.46 at its peak.
During the past year, Medicenna Therapeutics(MDNAF) stock moved between $0.57 at its lowest and $1.46 at its peak.
People also own
Based on the portfolios of people who own MDNAF. This list is generated using Robinhood data, and it’s not a recommendation.